NUVL Overview
Upcoming Projects (NUVL)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (NUVL)
-
Discussing the update of NVL-655 in ALK NSCLC from ESMO
Ticker: NUVL
Executed On: Oct 08, 2024 at 12:30 PM EDT -
Discussing the treatment landscape for ROS1 NSCLC and the potential of taletrectinib
Tickers: NUVB, NUVL, BMY, PFE
Executed On: Sep 24, 2024 at 11:00 AM EDT -
Examining the ESMO data on Nuvalent's NVL-655 (ALKove-1 study) and Roche's alectinib (P3 ALINA trial) for ALK+ NSCLC
Tickers: NUVL, RHHBY
Executed On: Nov 20, 2023 at 08:00 AM EST -
Examining the potential of Nuvalent's ROS1-selective inhibitor, NVL-520, in patients with advanced NSCLC
Ticker: NUVL
Executed On: Nov 15, 2022 at 04:30 PM EST
Upcoming & Overdue Catalysts (NUVL)
-
Don’t see a catalyst related to the company you care about? Create your own!
Strategic Initiatives (NUVL)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
